Literature DB >> 7020171

Immune responses to organ allografts. III. Marked decrease in medullary thymocytes and splenic T lymphocytes after cyclosporin A treatment.

W M Baldwin, I F Hutchinson, C J Meijer, N L Tilney.   

Abstract

Untreated LEW rats reject primarily vascularized Ag-B-incompatible LBNF1, BN, and WF cardiac allografts in 6 to 8 days. Cyclosporin A (CyA) administered 15 mg/kg/day i.m. for 7 days after grafting extends graft function greater than 100 days. Histological studies demonstrated that CyA treatment strikingly reduces the size and cellularity of the thymic medulla, splenic marginal zone, and splenic periarterial sheath by 97, 67 and 50%, respectively. These compartments are thought to contain cells of a single T lymphocyte lineage with helper and cytotoxic functions. CyA was less effective against cells in the thymic cortex and splenic red pulp, compartments thought to contain suppressor cells. CyA-induced depletion of lymphoid tissues was maximal 7 to 14 days after completion of treatment. All compartments recovered nearly normal morphology by 50 to 100 days, although hyperplastic nodules were found in spleens of three WF heart graft recipients during the recovery phase. CyA was more effective, histologically, in inhibiting the immune response to heart grafts from WF than from LBNF1 or BN donors. Within 3 days after LBNF1 or BN heart grafting, moderate antibody production occurred in the spleen (as noted by increase in Ig-positive immunoblasts) and vascular damage occurred in the grafts. These signs of rejection were delayed until 14 days in WF heart grafted rats. In none of the strain combinations were these early reactions followed by a vigorous cellular infiltrate. Thus, CyA seems to decrease preferentially cytotoxic and helper T lymphocyte responses to cardiac allografts.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7020171

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  11 in total

1.  Immunosuppression with cyclosporin A alters the thymic microenvironment.

Authors:  M Kanariou; R Huby; H Ladyman; M Colic; G Sivolapenko; I Lampert; M Ritter
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

Review 2.  Immunosuppressive therapy for renal transplantation.

Authors:  C B Carpenter; T B Strom
Journal:  Springer Semin Immunopathol       Date:  1984

3.  Cyclosporin A: pharmacologic activity on the immune system and effects in clinical organ transplantation.

Authors:  L H Block; P M Sutter; M J Mihatsch
Journal:  Klin Wochenschr       Date:  1983-11-02

4.  Effect of Cyclosporin A on rat thymus: time course analysis by immunoperoxidase technique and flow cytofluorometry.

Authors:  M Tanaka; K Shinohara; T Fukumoto; H Tanaka; T Kaneko
Journal:  Clin Exp Immunol       Date:  1988-05       Impact factor: 4.330

5.  Neonatal injections of cyclosporin enhance autoimmune diabetes in non-obese diabetic mice.

Authors:  P Saï; O Senecat; L Martignat; E Gouin
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

6.  Pathological changes in rats receiving cyclosporin A at immunotherapeutic dosage for 7 weeks.

Authors:  P H Whiting; J G Simpson; R J Davidson; A W Thomson
Journal:  Br J Exp Pathol       Date:  1983-08

7.  Effects of cyclosporin A on mouse lymphoid tissues.

Authors:  O Kai; R M Franklin
Journal:  Br J Exp Pathol       Date:  1983-10

8.  Cyclosporin A: a new advance in transplantation.

Authors:  B D Kahan
Journal:  Tex Heart Inst J       Date:  1982-09

Review 9.  Cyclosporin A. Clinical pharmacology and therapeutic potential.

Authors:  D J White
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

Review 10.  Cyclosporine: immunology, toxicity and pharmacology in experimental animals.

Authors:  A W Thomson; P H Whiting; J G Simpson
Journal:  Agents Actions       Date:  1984-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.